BCL2 and acute lymphoblastic leukemia: Accordingly, the treatment with Ruxolitinib (JAKi) reduced efficiently the expression of pro-survival BCL2 protein to a similar extent as IL7 withdrawal, and the combination with GSK-LSD1 totally reversed the protein ratio BCL2/BIM in Zeb2Tg ETP-ALL cells (Fig. 3A).